PMID- 26352242
OWN - NLM
STAT- MEDLINE
DCOM- 20160809
LR  - 20151009
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 30
IP  - 6
DP  - 2015 Nov
TI  - Ischaemic heart disease - a selected review of recent developments.
PG  - 657-62
LID - 10.1097/HCO.0000000000000230 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to highlight important and 
      interesting advances in the field of ischaemic heart disease that have occurred 
      over the last 18 months. It is focused on research that is likely to lead to 
      changes in clinical practice. RECENT FINDINGS: There is new evidence on 
      appropriate pharmacotherapy during angioplasty in both stable and unstable 
      patients. The use of pressure wire assessment has been shown to improve patient 
      outcome. The management of patients with ST elevation myocardial infarction 
      (STEMI) is likely to change with a reduction in the use of manual thrombectomy 
      and an increase in the treatment of nonculprit disease. SUMMARY: The optimal 
      duration of dual antiplatelet therapy in percutaneous coronary intervention 
      remains an intensely debated topic with contradictory results from major trials. 
      Pressure wire guided coronary intervention reduces the need for urgent 
      revascularization. The use of fractional flow reserve computed tomography has the 
      potential to revolutionize functional testing. The treatment of patients 
      presenting with ST elevation myocardial infarction is likely to change 
      dramatically. Heparin with bailout glycoprotein IIbIIIa-inhibitor (GPIIbIIIa-I) 
      appears superior to bivalirudin alone, although there is no longer a role for 
      routine manual thrombectomy. Multivessel PCI to establish complete 
      revascularization may become the gold standard in patients presenting with STEMI, 
      although larger trials are needed. Novel therapies are being devised for the 
      treatment of patients with intractable angina, but further work is required in 
      this area.
FAU - George, Sudhakar
AU  - George S
AD  - aInstitute of Translational Medicine, Queen Elizabeth Hospital, University 
      Hospitals Birmingham NHS Foundation Trust bUniversity of Birmingham, Birmingham, 
      UK.
FAU - Calvert, Patrick A
AU  - Calvert PA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Disease Progression
MH  - Humans
MH  - Myocardial Ischemia/*therapy
MH  - Myocardial Revascularization/*trends
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Treatment Outcome
EDAT- 2015/09/10 06:00
MHDA- 2016/08/10 06:00
CRDT- 2015/09/10 06:00
PHST- 2015/09/10 06:00 [entrez]
PHST- 2015/09/10 06:00 [pubmed]
PHST- 2016/08/10 06:00 [medline]
AID - 10.1097/HCO.0000000000000230 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2015 Nov;30(6):657-62. doi: 10.1097/HCO.0000000000000230.